Relay Therapeutics Analyst Ratings
Relay Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2023 | 145.16% | HC Wainwright & Co. | $33 → $19 | Maintains | Buy |
| 10/17/2023 | 325.81% | HC Wainwright & Co. | $30 → $33 | Maintains | Buy |
| 08/17/2023 | 287.1% | HC Wainwright & Co. | $32 → $30 | Maintains | Buy |
| 08/09/2023 | 325.81% | Oppenheimer | → $33 | Reiterates | Outperform → Outperform |
| 06/09/2023 | 312.9% | HC Wainwright & Co. | $46 → $32 | Maintains | Buy |
| 05/05/2023 | 209.68% | JMP Securities | $28 → $24 | Maintains | Market Outperform |
| 04/20/2023 | 61.29% | Jefferies | $16 → $12.5 | Upgrades | Underperform → Hold |
| 04/20/2023 | 338.71% | Stifel | $38 → $34 | Maintains | Buy |
| 04/19/2023 | 274.19% | JP Morgan | $42 → $29 | Maintains | Overweight |
| 04/19/2023 | 261.29% | JMP Securities | → $28 | Reiterates | → Market Outperform |
| 04/19/2023 | 274.19% | Raymond James | → $29 | Upgrades | Outperform → Strong Buy |
| 04/19/2023 | 93.55% | Barclays | $23 → $15 | Maintains | Equal-Weight |
| 04/18/2023 | 325.81% | Oppenheimer | → $33 | Maintains | Outperform |
| 04/13/2023 | 274.19% | Raymond James | → $29 | Initiates Coverage On | → Outperform |
| 04/05/2023 | 441.94% | JP Morgan | $45 → $42 | Maintains | Overweight |
| 03/07/2023 | 493.55% | HC Wainwright & Co. | $43 → $46 | Maintains | Buy |
| 02/03/2023 | 325.81% | Oppenheimer | → $33 | Initiates Coverage On | → Outperform |
| 01/19/2023 | 261.29% | JMP Securities | $38 → $28 | Maintains | Market Outperform |
| 11/07/2022 | 454.84% | HC Wainwright & Co. | $50 → $43 | Maintains | Buy |
| 09/30/2022 | 196.77% | Barclays | → $23 | Initiates Coverage On | → Equal-Weight |
| 09/14/2022 | 390.32% | JMP Securities | $35 → $38 | Maintains | Market Outperform |
| 09/12/2022 | 545.16% | HC Wainwright & Co. | $46 → $50 | Maintains | Buy |
| 09/02/2022 | 416.13% | Stifel | → $40 | Initiates Coverage On | → Buy |
| 08/09/2022 | 493.55% | HC Wainwright & Co. | $47 → $46 | Maintains | Buy |
| 06/06/2022 | 67.74% | Jefferies | → $13 | Initiates Coverage On | → Underperform |
| 05/24/2022 | 441.94% | Goldman Sachs | $49 → $42 | Maintains | Buy |
| 05/10/2022 | 506.45% | HC Wainwright & Co. | $54 → $47 | Maintains | Buy |
| 05/09/2022 | 351.61% | JMP Securities | $50 → $35 | Maintains | Market Outperform |
| 02/01/2022 | 480.65% | Berenberg | → $45 | Initiates Coverage On | → Buy |
| 08/17/2021 | 596.77% | HC Wainwright & Co. | $57 → $54 | Maintains | Buy |
| 07/21/2021 | 545.16% | B of A Securities | → $50 | Initiates Coverage On | → Buy |
| 01/29/2021 | 570.97% | JP Morgan | $36 → $52 | Maintains | Neutral |
| 12/15/2020 | 635.48% | HC Wainwright & Co. | $54 → $57 | Maintains | Buy |
| 12/08/2020 | 751.61% | JMP Securities | → $66 | Initiates Coverage On | → Market Outperform |
| 11/05/2020 | 596.77% | HC Wainwright & Co. | → $54 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/08/2023 | 145.16% | HC Wainwright & Co. | 33 美元 → 19 美元 | 维护 | 买 |
| 10/17/2023 | 325.81% | HC Wainwright & Co. | 30 美元 → 33 美元 | 维护 | 买 |
| 08/17/2023 | 287.1% | HC Wainwright & Co. | 32 美元 → 30 美元 | 维护 | 买 |
| 08/09/2023 | 325.81% | 奥本海默 | → 33 美元 | 重申 | 跑赢大盘 → 跑赢大盘 |
| 06/09/2023 | 312.9% | HC Wainwright & Co. | 46 美元 → 32 美元 | 维护 | 买 |
| 05/05/2023 | 209.68% | JMP 证券 | 28 美元 → 24 美元 | 维护 | 市场表现跑赢大盘 |
| 04/20/2023 | 61.29% | 杰富瑞集团 | 16 美元 → 12.5 美元 | 升级 | 表现不佳 → 持有 |
| 04/20/2023 | 338.71% | Stifel | 38 美元 → 34 美元 | 维护 | 买 |
| 04/19/2023 | 274.19% | 摩根大通 | 42 美元 → 29 美元 | 维护 | 超重 |
| 04/19/2023 | 261.29% | JMP 证券 | → 28 美元 | 重申 | → 市场跑赢大盘 |
| 04/19/2023 | 274.19% | 雷蒙德·詹姆 | → 29 美元 | 升级 | 跑赢大盘 → 强势买入 |
| 04/19/2023 | 93.55% | 巴克莱 | 23 美元 → 15 美元 | 维护 | 重量相等 |
| 04/18/2023 | 325.81% | 奥本海默 | → 33 美元 | 维护 | 跑赢大盘 |
| 04/13/2023 | 274.19% | 雷蒙德·詹姆 | → 29 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 04/05/2023 | 441.94% | 摩根大通 | 45 美元 → 42 美元 | 维护 | 超重 |
| 03/07/2023 | 493.55% | HC Wainwright & Co. | 43 美元 → 46 美元 | 维护 | 买 |
| 02/03/2023 | 325.81% | 奥本海默 | → 33 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 01/19/2023 | 261.29% | JMP 证券 | 38 美元 → 28 美元 | 维护 | 市场表现跑赢大盘 |
| 2022 年 7 月 11 日 | 454.84% | HC Wainwright & Co. | 50 美元 → 43 美元 | 维护 | 买 |
| 09/30/2022 | 196.77% | 巴克莱 | → 23 美元 | 启动覆盖范围开启 | → 重量相等 |
| 09/14/2022 | 390.32% | JMP 证券 | 35 美元 → 38 美元 | 维护 | 市场表现跑赢大盘 |
| 09/12/2022 | 545.16% | HC Wainwright & Co. | 46 美元 → 50 美元 | 维护 | 买 |
| 09/02/2022 | 416.13% | Stifel | → 40 美元 | 启动覆盖范围开启 | → 购买 |
| 08/09/2022 | 493.55% | HC Wainwright & Co. | 47 美元 → 46 美元 | 维护 | 买 |
| 2022 年 6 月 6 日 | 67.74% | 杰富瑞集团 | → 13 美元 | 启动覆盖范围开启 | → 表现不佳 |
| 2022 年 5 月 24 日 | 441.94% | 高盛 | 49 美元 → 42 美元 | 维护 | 买 |
| 05/10/2022 | 506.45% | HC Wainwright & Co. | 54 美元 → 47 美元 | 维护 | 买 |
| 05/09/2022 | 351.61% | JMP 证券 | 50 美元 → 35 美元 | 维护 | 市场表现跑赢大盘 |
| 2022 年 1 月 2 日 | 480.65% | 贝伦贝格 | → 45 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 8 月 17 日 | 596.77% | HC Wainwright & Co. | 57 美元 → 54 美元 | 维护 | 买 |
| 07/21/2021 | 545.16% | B of A 类证券 | → 50 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 1 月 29 日 | 570.97% | 摩根大通 | 36 美元 → 52 美元 | 维护 | 中立 |
| 2020 年 12 月 15 日 | 635.48% | HC Wainwright & Co. | 54 美元 → 57 美元 | 维护 | 买 |
| 12/08/2020 | 751.61% | JMP 证券 | → 66 美元 | 启动覆盖范围开启 | → 市场跑赢大盘 |
| 2020 年 5 月 11 日 | 596.77% | HC Wainwright & Co. | → 54 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for Relay Therapeutics (RLAY)?
Relay Therapeutics（RLAY）的目标价格是多少？
The latest price target for Relay Therapeutics (NASDAQ: RLAY) was reported by HC Wainwright & Co. on November 8, 2023. The analyst firm set a price target for $19.00 expecting RLAY to rise to within 12 months (a possible 145.16% upside). 18 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月8日公布了Relay Therapeutics（纳斯达克股票代码：RLAY）的最新目标股价。该分析公司将目标股价定为19.00美元，预计RLAY将在12个月内升至12个月内（可能上涨145.16％）。去年有18家分析公司公布了评级。
What is the most recent analyst rating for Relay Therapeutics (RLAY)?
Relay Therapeutics（RLAY）的最新分析师评级是多少？
The latest analyst rating for Relay Therapeutics (NASDAQ: RLAY) was provided by HC Wainwright & Co., and Relay Therapeutics maintained their buy rating.
Relay Therapeutics（纳斯达克股票代码：RLAY）的最新分析师评级由HC Wainwright & Co. 提供，Relay Therapeutics维持买入评级。
When is the next analyst rating going to be posted or updated for Relay Therapeutics (RLAY)?
Relay Therapeutics（RLAY）的下一次分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Relay Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Relay Therapeutics was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Relay Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Relay Therapeutics的最新评级是在2023年11月8日公布的，因此您应该预计下一个评级将在2024年11月8日左右公布。
Is the Analyst Rating Relay Therapeutics (RLAY) correct?
分析师评级 Relay Therapeutics (RLAY) 是否正确？
While ratings are subjective and will change, the latest Relay Therapeutics (RLAY) rating was a maintained with a price target of $33.00 to $19.00. The current price Relay Therapeutics (RLAY) is trading at is $7.75, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Relay Therapeutics（RLAY）评级维持不变，目标股价为33.00美元至19.00美元。Relay Therapeutics（RLAY）目前的交易价格为7.75美元，超出了分析师的预期区间。